US 11,939,616 B2
Compositions and methods for enforcing fucosylation of lactosaminyl glycans in human cells with alpha(1,3)-fucosyltransferases
Robert Sackstein, Pinecrest, FL (US)
Assigned to THE BRIGHAM AND WOMEN'S HOSPITAL, INC., Boston, MA (US)
Filed by The Brigham and Women's Hospital, Boston, MA (US)
Filed on Sep. 22, 2020, as Appl. No. 17/027,794.
Application 17/027,794 is a continuation of application No. PCT/US2019/023668, filed on Mar. 22, 2019.
Claims priority of provisional application 62/647,404, filed on Mar. 23, 2018.
Prior Publication US 2021/0017562 A1, Jan. 21, 2021
Int. Cl. A61K 35/12 (2015.01); C12N 9/10 (2006.01); C12P 21/00 (2006.01)
CPC C12P 21/005 (2013.01) [C12Y 204/01214 (2013.01)] 4 Claims
 
1. A process for custom engineering a fucosylated lactosaminyl glycan comprising:
(a) determining a desired enforced glycosylation pattern for a target human cell, wherein the enforced glycosylation pattern is selected from the group consisting of:
(i) sLex (+)>>Lex(+), with Di-Fuc-sLex (+), and VIM-2 (−); and
(ii) Lex(+), sLex (−), VIM-2 (−), and Di-Fuc-sLex (−);
(b) selecting an α(1,3)-fucosyltransferase VI capable of producing the desired glycosylation pattern; and
(c) contacting the target human cell with the selected α(1,3)-fucosyltransferase VI.